SOTIO Biotech is a clinical stage immunooncology company headquartered in Prague, Czech Republic. The company is developing a range of new cancer immunotherapies, with a focus on next-generation PD-1 inhibitors of cytokines, CAR-T cell therapy, and antibody drug conjugates (ADCs). Sotio’s patented technology aims to enhance the effectiveness and safety of these immunotherapies, potentially providing new treatment options for various cancer patients.
Key products and technologies
SOT201: The new generation of PD-1 inhibits cytokines, aiming to overcome the limitations of existing PD-1 inhibitors by targeting unique epitopes on the PD-1 receptor.
CAR-T cell therapy: Sotio is developing a patented technology to manufacture CAR-T cell therapies that are more effective and long-lasting than existing therapies.
Antibody drug conjugates (ADCs): Sotio is developing a new generation of ADCs aimed at improving the efficacy and safety of ADCs by using more effective ligands and payloads.
Clinical trials.
SOTIO is currently conducting multiple clinical trials to evaluate its novel immunotherapy in various cancers. The company is still actively developing new candidate products.
Partnership and cooperation
SOTIO has established partnerships with leading pharmaceutical companies and research institutions to support its clinical development and commercialization efforts.
Financial condition
SOTIO has a strong financial situation and financial support from leading investors. The company has the ability to advance its product line through clinical development and commercialization.
Future prospects
SOTIO is at the forefront of developing next-generation cancer immunotherapies. The company’s product line has the potential to address unmet needs in cancer treatment and potentially revolutionize the way cancer is treated.